3don MSN
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat schizophrenia failed ...
AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...
Irish Examiner on MSN1d
Profits fall by 27% at Abbvie's Botox plant at WestportAllergan first set up on a greenfield site outside Westport 47 years ago and it has provided a bonanza to the Co Mayo town.
On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy ...
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...
Irish Independent on MSN1d
Profits drop at Botox plant in Westport as revenues down by 4pcPre-tax profits at AbbVie’s global production facility for Botox, in Westport, last year declined by 27pc to $1.1bn (€1.04bn) ...
AbbVie’s setback was viewed as a victory for Bristol Myers Squibb Co., which in late September gained US approval for the first new type of schizophrenia drug in seven decades. Bristol shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback